BeiGene adopts GE ‘turnkey’ factory for anti-PD-1 mAb production

By Flora Southey contact

- Last updated on GMT

(Image: Getty/4045)
(Image: Getty/4045)

Related tags: Ge healthcare, China

BeiGene will use GE Healthcare Life Sciences’ ‘off-the-shelf’ factory to manufacture monoclonal antibodies in Guangdong Province, China.

BeiGene said it would adopt the KUBio factory to increase large-scale production of its immune-oncology therapies, including investigational anti-PD-1 monoclonal antibody (mAb), tislelizumab.

“Once approved, our commercial mAb products will [also] be manufactured there,” ​BeiGene spokesperson Liza Heapes told us.

KUBio is a pre-engineered facility designed around GE technology, such as the firm’s single-use biomanufacturing facility, FlexFactory. The current good manufacturing practice (cGMP)-compliant, modular construction can be built in approximately 18 months, and according to GE, can yield higher productivity by increasing the number of lots manufactured.

The first phase of the facility, located in the Ghangzhou region​, is expected to be completed and operational by the end of next year.

GE in China

BeiGene is familiar with GE Healthcare’s bioprocessing range, having adopted​ the company’s FlexFactory platform for its Suzhou mAb plant in 2015.

GE Healthcare has co-developed a number of biopharmaceutical sites in China, including Pfizer​, JHL​, Cellular Biomedicine Group​ (CBMG) and Clover Biopharmaceuticals, however according to GE’s manager of BioProcess, Olivier Loeillot, the firm continues to focus on the global market.

“We are operating and collaborating with biopharmaceutical companies globally. The Chinese market is growing fast and therefore we are seeing many KUBio and FlexFactory installations in China,” ​he said.

Related news

Show more

Related products

show more

Microaerobic Fermentation of Lactobacillus acidophilus

Microaerobic Fermentation of Lactobacillus acidophilus

Eppendorf for Bioprocess – Solutions that grow with you | 01-Oct-2019 | Application Note

We successfully performed microaerobic fermenta¬tion of a probiotic strain, Lactobacillus acidophilus, at a very low oxygen level, representing the natural...

Protect your bulk filtration and dispense step

Protect your bulk filtration and dispense step

Parker Bioscience Filtration | 22-Jul-2019 | Data Sheet

Does your process need greater protection when the value of your product is at its highest?

At the bulk filtration and container fill stage,...

rAAV Production in BioBLU® Single-Use Vessels

rAAV Production in BioBLU® Single-Use Vessels

Eppendorf for Bioprocess – Solutions that grow with you | 25-Jun-2019 | Application Note

Rising interest in gene therapy-based applications leads to increasing demands in scalable production systems for viral vectors. Find out how Cevec Pharmaceuticals...

Related suppliers

Follow us

Products

View more

Webinars